[New therapeutic targets in hypertension]

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Discovery

Background:

• Existing antihypertensive drugs are numerous, but challenges remain, particularly in treating resistant hypertension.
• Novel therapeutic strategies are crucial for advancing hypertension management.
• Some emerging treatments offer extended duration of action, potentially improving patient adherence.

Purpose of the Study:

• To review clinical data on novel therapeutic targets for hypertension.
• To highlight emerging drug candidates for resistant hypertension.
• To explore new treatment modalities with unique pharmacokinetic profiles.

Main Methods:

• Review of clinical trial data for new antihypertensive molecules.
• Analysis of therapeutic targets including the renin-angiotensin-aldosterone system.
• Evaluation of novel receptor modulators and enzyme inhibitors.

Main Results:

• Several novel targets are under development, focusing on resistant hypertension.
• Interventions targeting the renin-angiotensin-aldosterone system (e.g., angiotensinogen RNA interference, aldosterone synthase inhibition, non-steroidal aldosterone receptor antagonists) show promise.
• Dual endothelin receptor antagonists and NPR1 receptor agonists represent other key therapeutic avenues.

Conclusions:

• Emerging antihypertensive therapies offer new hope for resistant hypertension.
• Novel targets and drug candidates are expanding treatment options.
• Long-acting formulations could revolutionize current antihypertensive regimens.